Kornimate/medical-research-clean huggingface dataset:
clinical trial of tqb3002 in patients with advanced cancers

Conditions: Advanced Cancer

Summary: this is a phase i study to evaluate the safety, tolerability, and efficacy of tqb3002 in subjects with advanced cancers


Eligibility criteria:
inclusion criteria: * subjects voluntarily joined this study, signed the informed consent form, and had good compliance； * age: 18-75 years; eastern cooperative oncology group (ecog) score: 0-1 ; expected survival of more than 3 months； * histologically or cytologically diagnosed with advanced cancers * subjects with advanced malignancies who have failed standard therapy or lack effective treatment * major organs are functioning well； * female and male subjects of childbearing potential should agree to practice contraception for the duration of the study and for 6 months after the end of the study. exclusion criteria: * current concomitant presence of other malignancies within 5 years prior to the first dose； * unresolved toxicity above ctcae grade 1 due to any prior anti-tumor therapy * significant surgical treatment, biopsy, or significant traumatic injury within 4 weeks prior to the first dose * long-term unhealed wounds or fractures * cerebrovascular accident (including transient ischemic attack, intracerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism within 6 months prior to the first dose * swallowing dysfunction, active gastrointestinal diseases or other diseases that significantly affect the absorption, distribution, metabolism and excretion of the study drug, or previous subtotal gastrectomy * a history of psychotropic drug abuse and cannot be abstained from or have a mental disorder * subjects with any severe and/or uncontrolled disease
communication strategies to increase hpv vaccination intention

Conditions: Papilloma Viral Infection; Vaccine Hesitancy; Communication

Summary: this research aims to identify communication strategies to improve the uptake of vaccines using an experimental design, focusing on the human papillomavirus (hpv) vaccine, which is highly effective in preventing hpv-related cancers. however, low hpv vaccination rates among adults remain a significant public health challenge. although randomized controlled trials (rcts) have demonstrated that interventions can increase vaccine uptake in children, few rcts have been conducted on adults. to address this gap, a multidisciplinary investigative team with expertise in communication, medicine, nursing, and behavior-change intervention research, and a history of extensive collaboration, will conduct a survey experiment on a national sample of over 3,689 adults to identify the most promising theory-based messages to strengthen hpv vaccine intentions.


Eligibility criteria:
inclusion criteria: * 18-45 years old exclusion criteria: * under 18 and over 45 years old * received hpv vaccine or unsure about receipt
strength training and adls in childhood leukemia and lymphoma patients

Conditions: Childhood Cancer

Summary: reduced activity levels and reduced muscular strength could severely impair the activities of daily living (adls) in pediatric leukemia and non-hodgkin lymphoma patients. increased muscle strength is associated with improved accomplishment of adls and consequently greatest possible normality, autonomy and mobility. primary outcome of this rct (n=20/20) is the analysis of effects of a treatment-associated and close to every day life strength training (2-3 times/week) compared to a general exercise program (standard care).


Eligibility criteria:
inclusion criteria: * diagnosed with acute leukemia or non-hodgkin lymphoma * diagnosed and/or treated at the kinderklinik münchen schwabing, technische universität münchen * informed consent as documented by signature exclusion criteria: * medical contraindications regarding strength training (e.g. risk of bleeding, ...) * contraindications to one of the inclusion criteria mentioned above * inability to follow the procedures and understand the intervention and assessments of this study, e.g. due to cognitive impairment, language problems, psychological disorders etc.

Keywords: exercise strength training activities of daily living childhood cancer leukemia non-hodgkin lymphoma
a warmer temperature decrease propofol injection pain

Conditions: Injection Site Irritation; Propofol Syndrome; Temperature Change, Body

Summary: propofol injection pain will be surfed by up to 70-80 percentage by the patients who induced by propofol. temperature of operating room was set to a certain range in normal clinical practice, which is 22- 26 centigrade. warm feeling will make skin vassal dilated and more blood will pass through to bring more heat out of our body. it had been reported that a bigger venous vessels will get less propofol injection pain. the investigators hypothesis that patients who stayed in a warmer room temperature will surf less injection pain while compare to a normal setting room temperature.


Eligibility criteria:
inclusion criteria: * asa i\~iii, aged 18，scheduled or emergency surgery with general anesthesia. exclusion criteria: * a history of allergy to propofol, allergy to soybean oil * with peripheral blood diseases.
internet-based rehabilitation aftercare focusing on physical activity promotion in persons with copd

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: the aim of the study is to evaluate a 12-week internet-based rehabilitation aftercare program with an emphasis on physical activity promotion for persons with copd. the program starts directly after an inpatient pulmonary rehabilitation program. it includes monitoring and promotion of physical activity, progressive resistance and endurance training, education through online learning modules and continuous support from a therapist.


Eligibility criteria:
inclusion criteria: * main diagnosis for the pulmonary rehabilitation is an international classification of diseases-code j44.- (other chronic obstructive pulmonary disease) at all 2011 global initiative for chronic obstructive lung disease (gold) classifications a-d and stages 1-4. * internet access at home * owning a smartphone with the operating system android or ios * basic computer and internet skills (e. g. using web browser) * ability to operate a smartphone (especially to install mobile applications) * ability to read, write and comprehend as well as communicate electronically exclusion criteria: * severe concomitant disease, which will affect the ability to be physically active more than copd for example, cancer or severe cardiac, neurological, orthopaedic or metabolic comorbidities) * cognitive impairment that hampers study implementation * lack of ability to speak german

Keywords: pulmonary disease, chronic obstructive exercise physical activity promotion behavior change internet-based intervention physical literacy rehabilitation aftercare mhealth telerehabilitation feasibility
muscle strength evaluations in ankylosing spondylitis

Conditions: Ankylosing Spondylitis

Summary: this study evaluates how the trunk and proximal girdle muscles are affected in male patients with ankylosing spondylitis, compared to healthy controls.

ankylosing spondylitis is a chronic, inflammatory rheumatic disease with an unclear etiology which causes back pain and affects the functionality of axial skeleton. besides the effect upon axial skeleton, the disease also affects the peripheral joints. in most patients, tenuous affection of peripheral joints occurs however, in some others the disease causes impaired spinal mobility and articular instability. this causes proximal girdle muscles and trunk muscles of the patients to be exposed to excessively stress and in conclusion deformities develop. maximum force generated by a muscle or muscle group directly effects the physical ability of an individual, and manual muscle dynamometers are used to directly evaluate the muscle strength. in this manner the investigators aim to evaluate trunk and proximal girdle muscles' powers in male patients with ankylosing spondylitis and analyze the correlation between muscle powers, and functionality and disease activity.

Eligibility criteria:
inclusion criteria: 1. having a diagnosis of ankylosing spondylitis according to modified newyork criteria 2. being male 3. aged ≥18 exclusion criteria: 1. severe cardiac or pulmonary or renal disease 2. accompanying fibromyalgia 3. severe psychiatric disorder 4. other disease limiting spinal, shoulder or hip range of motion 5. myopathy, neuropathy or radiculopathy that may cause muscle weakness 6. using high dose steroids 7. endocrinological disorders 8. malignancy 9. pregnancy

Keywords: muscle powers functionality disease activity
bilateral quadraus lumborum block in patients under going cystectomy

Conditions: Pain, Acute

Summary: ultrasound guided quadratus lumborum will be given for patients under going partial or complete urinary bladder removal.

ultrasound guided quadratus lumborum will be given for patients under going partial or complete urinary bladder removal.

Eligibility criteria:
inclusion criteria: * elective surgery * patients between 30 and 60 years exclusion criteria: * coagulopathy * infection at insertion site * patient refusal
the effect of north american ginseng on blood pressure in individuals with hypertension

Conditions: Hypertension

Summary: to determine the effect of north american ginseng on blood pressure in individuals with hypertension.

ginseng lacks proper clinical scrutiny for its effect on blood pressure (bp), in spite of observational evidence linking its intake to hypertension. this should be addressed considering the potential overlap between the prevalence of ginseng use and hypertension. we undertook a single centre, randomized, controlled, double-blinded, crossover trial to determine the effect of north american ginseng (nag) on 24-hour bp and renal function. after a 4-week placebo run-in, we randomly assigned participants to nag or placebo treatment for 12-weeks at a dose of 3g/day. this was followed by an 8-week washout, and a subsequent 12-week period in which the opposite treatment was consumed. at run-in, and at weeks 0 and 12 of each treatment period, participants were fitted with an ambulatory bp monitor to assess 24-hour bp and serum cystatin c was measured.

Eligibility criteria:
inclusion criteria: * aged 18 to 85 years * hypertension as defined by the use of antihypertensive drugs or a seated systolic blood pressure greater than or equal to 140 mm hg or a diastolic bp greater than or equal to 90 mm hg at each of 3 pre-study visits. exclusion criteria: * secondary hypertension * diabetes * kidney * liver disease * unstable angina * ginseng use for two months prior to or during the study * any changes in the type or dose of antihypertensive drugs one month prior to or during the study

Keywords: hypertension blood pressure ambulatory blood pressure monitoring complementary and alternative medicine herbal north american ginseng panax quinquefolius
photodynamic therapy for line infection prevention (plip): pilot study on healthy volunteers.

Conditions: Light; Therapy, Complications

Summary: we are evaluating the effect of methylene blue and visible light activation on the microbiome of the skin.

antiseptics are routinely utilized to prevent infections of vascular catheters. we are evaluating the addition of methylene blue and light activation on skin to determine whether this inexpensive and non-toxic treatment can decrease skin pathogens and prevent blood stream infections of long-term vascular catheters. this is a pilot study of normal volunteers to determine the effect on the microbiome of the addition of methylene blue and light activation on antiseptic-treated skin.

Eligibility criteria:
inclusion criteria: * normal individuals without skin problems exclusion criteria: * smokers * diabetics * atopic dermatitis * g-6-pd deficiency * eczema * other skin conditions * allergies to methylene blue or chlorhexadine
study of irofulven in combination with oxaliplatin in patients with advanced solid tumors

Conditions: Liver Cancer

Summary: the purpose of this study is to determine the maximum tolerated dose (mtd) and to investigate the efficacy, safety and pharmacokinetics of irofulven combined with oxaliplatin in patients with advanced solid tumors.


Eligibility criteria:
inclusion criteria: 1. signed informed consent obtained prior to initiation of any study-specific procedures and treatment. 2. malignant solid tumor confirmed by a biopsy sample. 3. pancreatic, endometrial, gastric, and hepatocellular cancer patients that have exhausted standard treatment options. 4. measurable disease according to recist. 5. 18 years of age or older. 6. eastern cooperative oncology group (ecog) performance status (ps): 0-1. 7. life expectancy greater than 3 months. 8. previous anticancer treatment must be discontinued at least 4 weeks prior to first dose of study treatment (6 weeks for mitomycin c, 8 weeks for bicalutamide). 9. patients of reproductive age must be using effective contraceptive methods. 10. negative pregnancy test for patients of reproductive potential. exclusion criteria: 1. prior therapy with irofulven or oxaliplatin. 2. patients who have had radiation therapy to more than 30% of the bone marrow prior to entry into the study. 3. prior chemotherapy with nitrosoureas or high dose carboplatin (auc \> 6), prior mitomycin c cumulative dose greater than or equal to 25 mg/m², prior bone marrow transplant or intensive chemotherapy with stem cell support. 4. presence of any serious concomitant systemic disorders incompatible with the study (e.g., uncontrolled congestive heart failure, active infection). 5. any previous history of another malignancy (other than cured basal cell carcinoma of the skin or cured in-situ carcinoma of the cervix) within 5 years of study entry, unless the active malignancy can be unmistakably identified by evidence such as recent biopsies or tumor specific markers. 6. treatment with any other investigational agent, or participation in another clinical trial within 28 days prior to study entry. 7. pregnant or lactating patients or any patient with childbearing potential not using adequate contraception. 8. patients with retinopathy or significant visual impairment not correctable by refractory lens will be enrolled on a case by case basis according to the expected benefit ratio, taking into account the malignant disease and the existence of an objective decreased visual acuity and its degree. please note: there are additional criteria that must be met in order to be eligible for this study.

Keywords: irofulven oxaliplatin
prospective study on asthma control

Conditions: Asthma

Summary: accordingly, the new update of the global initiative for asthma (gina) guidelines 2006 is based on the control of the disease and attempts to quantify and graduate the level of control by using a classification of asthmatic subjects into controlled,partly controlled and uncontrolled groups. achieving and maintaining optimal asthma control is a major goal of asthma management. although the results of clinical trials advocate that asthma control can be reached in most patients, there is evidence that many subjects with asthma have poorly controlled disease and that there is a significant gap between the treatment goals and the current level of asthma control achieved in the general population. the aim of this study is to assess the prevalence of uncontrolled and partly controlled asthma in italy using a patient-based tool such as asthma control test.


Eligibility criteria:
inclusion criteria: * written informed consent obtained * male or female patients with asthma diagnosis (at least 6 months) * ability to understand and fill in questionaires exclusion criteria: * patients included in a clinical trial within the last 12 weeks * patients with serious illnesses * pregnant women
eye plaque brachytherapy for ocular melanoma

Conditions: Ocular Melanoma

Summary: this prospective registry study will evaluate doses utilized in eye plaque brachytherapy for the treatment of ocular melanoma and their associated outcomes. the goal of this study is to evaluate if lower doses of radiation can maintain high local control rates while minimizing the toxicities related to radiation therapy.


Eligibility criteria:
inclusion criteria: * patients 18 years of age or older with unilateral primary choroidal melanoma * patients with diagnosis of small or medium ocular melanomas amenable to plaque brachytherapy (as determined by treating ocular oncologist). typically this would include tumors with apical height ≤10mm and basal diameter ≤16mm (small and medium tumors per coms (collaborative ocular melanoma study) * patients with no clinical evidence of metastatic disease as confirmed by negative staging imaging (ct, mri, and/or ultrasound) * patients with best-corrected visual acuity in the fellow eye of 20/200 or better * patients must be treated with isoaid eye physics eye plaques exclusion criteria: * patients whose tumors are circumferential around the optic disc and cannot be adequately covered by the prescription dose are ineligible. * similarly, patients with extrascleral tumor extension detected during echography or clinical exam, diffuse, ring or multifocal tumors that cannot be encompassed in a single episcleral plaque or tumors judged to be predominantly ciliary body or iris melanoma will be considered ineligible * previous treatment for ocular melanoma in either eye or treatment of any condition secondary to the tumor are ineligible. * patients with a history of other primary or metastatic cancers are not eligible, except for non-melanotic skin cancers * patients with extraocular disease

Keywords: eye plaque brachytherapy
hpv-cytology testing versus cytology testing for the detection of high grade cin

Conditions: Cervical Cancer; Cervical Intraepithelial Neoplasia

Summary: to compare the effects of conventional cytology testing with concommitant hpv-cytology testing for the detection of high grade cervical lesions in primary cervical cancer screening in hong kong hypotheses: 1. there is a significant difference in the number of cin2+ cases detected between the cytology testing group and the cytology-hpv co-testing group at baseline. 2. significantly more cin2+ cases will be detected at the second round of screening among participants with normal cytology result in the control arm than those with normal cytology and negative hpv results in the intervention arm.


Eligibility criteria:
inclusion criteria: * ethnic chinese women aged 30 to 60 years who have completed a written consent * women who have not attended screening for the past 3 years or more will be given priority exclusion criteria: * currently pregnant * without a cervix * congenital abnormalities of the lower genital tract * previous history of invasive cervical cancer * who has been followed-up or treated for an abnormal cytology result in the past 12 months * who are unable to provide consent

Keywords: cervical intraepithelial neoplasia, grade iii cervical intraepithelial neoplasia, grade ii
panvac™-vf vaccine for the treatment of metastatic pancreatic cancer after failing a gemcitabine-containing regimen

Conditions: Pancreatic Cancer

Summary: the objectives of this multi-center, randomized, controlled trial are to evaluate the safety and efficacy of panvac-vf in combination with granulocyte-macrophage colony-stimulating factor (gm-csf) versus best supportive care or palliative chemotherapy.

panvac-vf is an investigational cancer vaccine. the vaccine is based on the theory that the body can be taught to fight cancer by directing the immune system to attack specific targets found on cancer cells. these targets are called tumor associated antigens, or taa's. this trial will help determine if this vaccine can help fight cancer. all patients will be required to sign an informed consent prior to the performance of any study-related procedures. patients will be screened for eligibility within 14 days prior to their anticipated treatment start date (day 0). patients who meet all inclusion and exclusion criteria will be centrally randomized into the study and will receive a unique patient identification number and a treatment assignment. the ratio of active treatment to control is 1:1 (panvac-vf: best supportive care or palliative chemotherapy).

Eligibility criteria:
inclusion criteria: * patients \> 18 years of age who have been vaccinated against smallpox; * histologically confirmed diagnosis of adenocarcinoma of the pancreas; * patient has metastatic (stage iv) disease; * ecog performance status 0-1; * failed a gemcitabine-containing chemotherapeutic regimen within 3 months of study entry. exclusion criteria: * prior or concurrent immunotherapy for cancer; * radiation therapy within 28 days prior to registration; * systemic corticosteroid therapy (except inhaled or topical steroids) within 28 days of registration; * significant cardiovascular abnormalities or diseases; * known positive for hiv, hepatitis b and/or c; * evidence of immunodeficiency or immune suppression.

Keywords: metastatic
study of pretargeted radioimmunotherapy of a anti-cea bispecific antibody and lu177-labeled peptide in colorectal cancer

Conditions: Colorectal Neoplasms

Summary: this study will investigate the toxicity, safety and pharmacokinetics of pretargeted radioimmunotherapy with anti-cea x anti-hapten bispecific antibody tf2 and lu-177-labeled di-hsg-dota peptide imp-288. furthermore, the sensitivity of pretargeted imaging with in-111-labeled imp-288 as compared to standard methods of tumor detection, and the preliminary efficacy of the therapy.

pretherapy cycle with imp-288 labeled in111.

Eligibility criteria:
inclusion criteria: * patients with cea expressing advanced colorectal tumors for which no standard treatment is available * who performance status: 0 or 1 * having normal hematological function: neutrophils \> 1.5 x 109/l; platelet count \> 150 x 109/l, without transfusion during the previous month; hemoglobin \> 5.6 mmol/l * total bilirubin \< 2 x upper limit of normal (uln) * asat, alat \< 3 x uln * serum creatinine \< 2 x uln * cockcroft clearance \> 50 ml/min * negative pregnancy test for women of child¬bearing potential (urine or serum) * age over 18 years * ability to provide written informed consent exclusion criteria: * known metastases to the brain * chemotherapy, external beam radiation or immunotherapy within 4 weeks prior to study. limited field external beam radiotherapy to prevent pathological fractures is allowed, when unirradiated, evaluable lesions elsewhere are present. * prior angiogenesis inhibitors within 4 weeks; bevacizumab within 8 weeks * cardiac disease with new york heart association classification of iii or iv * patients who are pregnant, nursing or of reproductive potential and are not practicing an effective method of contraception * any unrelated illness, e.g. active infection, inflammation, medical condition or laboratory abnormalities, which in the judgement of the investigator will significantly affect patients' clinical status * life expectancy shorter than 6 months.

Keywords: radioimmunotherapy pretargeting bispecific antibody lutetium 177 phase i clinical trial